Phlebitis. Phlebitis and phlebitis of other sites
Conditions
Interventions
Intervention 1: Intervention
1: Splinting of the Amiodarone injection site with 2types of splints (designed by Kalay-e Pezeshki-e Ghalb Company): one for of the wrist and the other for the elbow. Int
Prevention
Intervention
1: Splinting of the Amiodarone injection site with 2types of splints (designed by Kalay-e Pezeshki-e Ghalb Company): one for of the wrist and the other for the elbow
2: No splinting at the site of Amiodarone injection
Sponsors
Tehran University of Medical Sciences, Vice Chancellor For Research
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Age between 18 and 65 years 2- Amiodarone administration for atrial fibrillation or ventricular tachycardia 3- Starting dose of Amiodarone administration at CCU 4- Informed consent of the patient regarding the use of the splint. In case of the patient’s incapacity, informed consent will be obtained from the patient’s first-degree relatives (e.g., parents). The patients will be reassured that their treatment course will not be affected by non-participation in the study. Exclusion criteria: 1- History of cancer and chemotherapy, deep vein thrombosis, renal failure and dialysis, consumption of broad-spectrum antibiotics and steroids 2- Removal of the splint in consequence of the patient’s agitation 3- Refusal to give consent for participation in the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: Checking the injection site for 24 hours, starting from 1 hour after the injection of Amiodarone. Method of measurement: Self-report of pain at the injection site.;Redness. Timepoint: Checking the injection site for 24 hours, starting from 1 hour after the injection of Amiodarone. Method of measurement: Checking the injection site for redness at 1 hour intervals.;Inflammation. Timepoint: Checking the injection site for 24 hours, starting from 1 hour after the injection of Amiodarone. Method of measurement: Checking the injection site for inflammation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Injection site infection. Timepoint: Observation and checking of the injection site at 1 hour intervals until the resolution of the signs of phlebitis. Method of measurement: The observation and checking of injection site. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarah Ayatollah Zadeh Esfahani
Tehran Heart Center Hospital
Outcome results
None listed